Selank vs Semax: Comparing Russian Nootropic Peptides

**Disclaimer:** This article is provided for educational and research purposes only. Selank and [Semax](/research/semax-cognitive) are approved as medications in Russia and some CIS countries but are not FDA-approved in the United States. Nothing in this article constitutes medical advice.

Introduction

Selank and Semax are two synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, each derived from endogenous regulatory peptides but designed with enhanced metabolic stability. Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, while Semax is derived from the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10). Despite their shared Russian academic origins and overlapping classification as "nootropic peptides," they operate through distinct neurochemical mechanisms and target different aspects of cognitive and emotional function.

Molecular Origins

Selank: The Tuftsin Analogue

Selank (TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide that consists of the native tuftsin sequence (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension that confers resistance to aminopeptidase degradation. Tuftsin itself is a tetrapeptide naturally cleaved from the Fc region of immunoglobulin G (IgG) heavy chain by two sequential enzymatic reactions: leukokinin in the spleen and tuftsin endocarboxypeptidase on the outer surface of neutrophils. Native tuftsin has a plasma half-life of only minutes due to rapid enzymatic degradation, but Selank's Pro-Gly-Pro tail extends its biological activity substantially.

Zozulya et al. (2008) reviewed Selank's pharmacological profile, noting that while it retains the immunomodulatory properties of tuftsin (phagocytosis stimulation, natural killer cell activation), it also demonstrates significant anxiolytic and nootropic effects not attributable to the parent tetrapeptide alone. This suggests that the Pro-Gly-Pro extension either alters receptor interactions or confers novel binding properties.

Semax: The ACTH(4-10) Analogue

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a seven-amino-acid peptide consisting of the ACTH(4-10) fragment with the same Pro-Gly-Pro stabilizing extension used in Selank. The ACTH(4-10) fragment was identified decades ago as the minimal sequence of ACTH that retains nootropic activity while lacking the steroidogenic effects of the full 39-amino-acid hormone. Ashmarin and colleagues at the Institute of Molecular Genetics developed Semax to exploit this dissociation between cognitive and hormonal effects.

Critically, Semax does not stimulate the adrenal cortex or increase cortisol production. The steroidogenic activity of ACTH resides in the N-terminal ACTH(1-24) sequence and requires receptor interactions that the (4-10) fragment does not support. Levitskaya et al. (2019) confirmed that Semax acts as a melanocortin system modulator, engaging MC3 and MC4 receptors in the brain without peripheral adrenal effects.

Mechanisms of Action

Selank: GABAergic and Enkephalinase Modulation

Selank's anxiolytic mechanism is primarily mediated through the GABAergic system. Seredenin et al. (1998) demonstrated that Selank modulates GABA-A receptor function, potentiating GABAergic inhibitory neurotransmission in a manner comparable to classical anxiolytics but without the sedation, tolerance, or dependence associated with benzodiazepines. The peptide does not bind directly to the benzodiazepine site on GABA-A receptors; rather, it appears to modulate receptor sensitivity through allosteric or indirect mechanisms.

Additionally, Selank inhibits enkephalinase (neprilysin/CD10), the enzyme responsible for degrading enkephalins --- endogenous opioid peptides involved in mood regulation, pain modulation, and stress responses. By slowing enkephalin degradation, Selank increases the availability of these endogenous opioids, contributing to its anxiolytic and mood-stabilizing effects without direct opioid receptor agonism.

Selank also influences monoamine metabolism. Research has shown that Selank administration alters the turnover of serotonin, dopamine, and norepinephrine in specific brain regions, including the hypothalamus and hippocampus. Kozlovskii et al. (2003) reported that Selank's effects on monoamine balance are most pronounced under conditions of stress or anxiety, suggesting a state-dependent mechanism of action that normalizes neurotransmitter imbalances rather than producing tonic changes.

Semax: BDNF and Trophic Factor Upregulation

Semax's primary cognitive mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB. Dolotov et al. (2006) demonstrated that Semax administration increased BDNF mRNA expression in the rat hippocampus and basal forebrain, regions critical for memory consolidation and cholinergic function. BDNF is the primary neurotrophin supporting long-term potentiation (LTP), dendritic branching, and synaptic plasticity --- the cellular substrates of learning and memory.

Semax also upregulates nerve growth factor (NGF) in certain brain regions, though its effects on BDNF are more robust and consistently reported. The trophic factor upregulation is thought to underlie Semax's demonstrated ability to enhance cognitive performance in both healthy subjects and those with cognitive impairment.

Through its melanocortin receptor activity, Semax modulates inflammatory pathways in the central nervous system. Dmitrieva et al. (2010) showed that Semax altered the expression of over 250 genes in rat brain tissue following ischemic injury, with significant enrichment of neuroprotective and anti-inflammatory pathways. Many of the upregulated genes were involved in neurotrophic signaling, cell survival (Bcl-2 family), and synaptic plasticity.

Clinical Applications in Russia

Both peptides are approved in Russia and administered intranasally, which is notable because intranasal delivery bypasses first-pass hepatic metabolism and provides direct access to the brain via the olfactory and trigeminal nerve pathways.

Selank is approved in Russia as an anxiolytic for generalized anxiety disorder and is marketed under the trade name Selank. Clinical studies conducted in Russian institutions have reported efficacy comparable to medazepam (a benzodiazepine) for anxiety reduction, but without the cognitive impairment, sedation, or dependence potential. Selank is typically administered at 250--300 mcg per day intranasally.

Semax is approved for several indications in Russia, including cognitive impairment, stroke recovery, optic nerve atrophy, and ADHD in children. It is marketed at concentrations of 0.1% and 1% intranasal solutions. For cognitive enhancement, typical dosing is 200--600 mcg per day. For stroke recovery, higher doses (up to 12 mg/day intravenously) have been used in Russian clinical settings.

Head-to-Head Comparison

| Parameter | Selank | Semax |

|-----------|--------|-------|

| Parent peptide | Tuftsin (Thr-Lys-Pro-Arg) | ACTH(4-10) (Met-Glu-His-Phe) |

| Primary target | GABAergic system, enkephalinase | BDNF/TrkB, melanocortin receptors |

| Primary effect | Anxiolytic, stress reduction | Cognitive enhancement, neuroprotection |

| Monoamine effects | Normalizes 5-HT, DA, NE under stress | Modulates DA via melanocortin system |

| Immunomodulation | Strong (tuftsin-derived) | Moderate (anti-inflammatory) |

| Administration | Intranasal, 250--300 mcg/day | Intranasal, 200--600 mcg/day |

| Stabilizing motif | Pro-Gly-Pro (C-terminal) | Pro-Gly-Pro (C-terminal) |

The key distinction is functional: Selank is primarily anxiolytic with secondary cognitive effects, while Semax is primarily pro-cognitive with secondary neuroprotective effects. Selank calms the neurochemical environment (GABAergic potentiation, enkephalin preservation, monoamine normalization), creating conditions conducive to cognitive function by reducing anxiety-driven interference. Semax directly enhances the molecular machinery of learning and memory (BDNF upregulation, synaptic plasticity, trophic support).

Summary

Selank and Semax share a common design philosophy --- stabilized analogues of endogenous regulatory peptides with enhanced metabolic stability via a Pro-Gly-Pro C-terminal extension --- but target fundamentally different neurobiological systems. Selank's tuftsin-derived anxiolytic mechanism operates through GABAergic modulation and enkephalinase inhibition, making it primarily relevant to anxiety and stress-related research. Semax's ACTH(4-10)-derived nootropic mechanism operates through BDNF upregulation and melanocortin receptor modulation, making it primarily relevant to cognitive enhancement and neuroprotection research. Researchers studying the intersection of emotional regulation and cognitive performance may find both peptides relevant, as anxiety and cognition share overlapping neurochemical substrates.

*This article is provided for informational and research purposes only. Viking Labs does not sell products intended for human consumption, and nothing in this article should be construed as medical advice.*